NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.87 -0.70 (-0.90%) GOLD FUTURES
2,333.30 -59.60 (-2.49%) DOW
39,065.26 -605.78 (-1.53%) Bitcoin GBP
52,676.61 -2,301.56 (-4.19%)
IDEAYA Biosciences, Inc. (IDYA)
After hours:
| Previous close | 41.38 |
| Open | 41.58 |
| Bid | 38.33 x 100 |
| Ask | 38.49 x 100 |
| Day's range | 38.23 - 41.58 |
| 52-week range | 20.90 - 47.74 |
| Volume | |
| Avg. volume | 688,704 |
| Market cap | 2.91B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update, and announced financial results for the first quarter ended March 31, 2024.
- PR Newswire
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.
- PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (
